CJC-1295 No DAC

Description

CJC-1295 (no DAC), also known as Modified GRF (modGRF 1-29), is an advanced peptide analogue of growth hormone–releasing hormone (GHRH) that was originally developed through biomedical research in the 1980s. This refined, truncated version of GHRH was engineered to increase stability and biological activity, allowing it to interact more effectively with the body’s growth hormone signaling system. Rather than supplying growth hormone directly, CJC-1295 (no DAC) encourages the body to naturally release its own GH, supporting a more balanced and physiological approach to performance and recovery.

Extensive research has highlighted the peptide’s broad potential across multiple areas of health and performance. Studies have associated Modified GRF with enhanced muscle repair and development, making it particularly valuable in recovery-focused and performance-oriented applications. Its ability to accelerate tissue healing has also generated interest in wound recovery and rehabilitation support. At the skeletal level, CJC-1295 (no DAC) has been linked to improved bone density and structural integrity, helping support long-term mobility and resilience.

In addition to musculoskeletal benefits, this peptide shows promise in supporting metabolic health. Research suggests CJC-1295 (no DAC) may contribute to increased fat oxidation and improved energy utilization, making it appealing for those focused on body composition and weight management. It has also been associated with better glucose regulation, which may support balanced blood sugar levels and overall metabolic efficiency. Early findings further suggest a role in immune support, as growth hormone plays an important part in cellular repair and immune system regulation.

Because of its natural mechanism of action and research-backed design, CJC-1295 (no DAC) has become one of the most respected compounds in the peptide research space. Ongoing scientific interest continues to refine how this peptide may best be applied, with continued studies aimed at further understanding its optimal use, long-term impact, and safety profile.

As with all investigational compounds, individual responses may vary, and ongoing research is essential to fully establish clinical applications. However, the accumulated body of research positions CJC-1295 (no DAC) as a compelling innovation in the pursuit of enhanced recovery, improved metabolism, and healthier aging.

Comes in 10mg vial

Provided as lyophilized powder intended strictly for experimental and research applications.